Cigna director granted 782 common shares

Cigna Group director Philip Ozuah received a stock award that increased his direct ownership.

Rhea-AI Filing Summary

Cigna Group director Philip Ozuah received a stock award that increased his direct ownership. On April 22, 2026, he acquired 782 shares of Cigna common stock through a grant/award acquisition at a stated price of $0.00 per share. After this award, his directly held position rose to 2,583 common shares. This appears to be a routine equity compensation grant rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 782 shares

Grant/Award 1 txn

Insider Ozuah Philip

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $.01 Par Value	782	$0.00	$0.00

Holdings After Transaction: Common Stock, $.01 Par Value — 2,583 shares (Direct)

Key Figures

Shares granted: 782 shares Price per share: $0.00 per share Shares owned after: 2,583 shares

3 metrics

Shares granted 782 shares Grant/award acquisition on April 22, 2026

Price per share $0.00 per share Stated transaction price for the grant

Shares owned after 2,583 shares Direct common stock holdings following the transaction

Key Terms

Form 4, grant/award acquisition, Common Stock, $.01 Par Value, non-derivative

4 terms

Form 4 regulatory

"What did Cigna Group (CI) director Philip Ozuah report in this Form 4?"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

grant/award acquisition financial

"he acquired 782 shares of Cigna common stock through a grant/award acquisition"

Common Stock, $.01 Par Value financial

"security_title: Common Stock, $.01 Par Value"

non-derivative financial

"The filing reports only a non-derivative acquisition of 782 common shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cigna Group (CI) director Philip Ozuah report in this Form 4?

Director Philip Ozuah reported receiving a grant of 782 Cigna Group common shares. The award increased his directly owned stake to 2,583 shares, reflecting routine equity-based compensation rather than an open-market stock purchase or sale.

How many Cigna Group (CI) shares did Philip Ozuah acquire and at what price?

Philip Ozuah acquired 782 Cigna Group common shares at a stated price of $0.00 per share. The transaction is described as a grant or award, indicating it is compensation-related rather than a market transaction involving cash paid for the stock.

What are Philip Ozuah’s Cigna Group (CI) holdings after this reported grant?

Following the April 22, 2026 transaction, Philip Ozuah directly holds 2,583 Cigna Group common shares. This total reflects the addition of 782 shares received as a grant or award, according to the ownership figures disclosed in the Form 4 filing.

Was the Cigna Group (CI) transaction by Philip Ozuah a market buy or sell?

The transaction is classified as a grant or award acquisition, not an open-market buy or sell. Ozuah’s 782 new shares were received at a stated price of $0.00 per share, indicating equity compensation rather than a discretionary trading decision.

Does this Cigna Group (CI) Form 4 show any derivative or option exercises?

No derivative or option exercises are shown in this Form 4 excerpt. The filing reports only a non-derivative acquisition of 782 common shares as a grant or award, with no remaining derivative positions listed in the accompanying derivative summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:48 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ozuah Philip

(Last) (First) (Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD CONNECTICUT 06002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 Par Value	04/22/2026		A		782	A	$0	2,583	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	Tyler Gratton, attorney-in-fact	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)